Comparison of the Mean Duration of 3rd Stage of Labour Between Intraumbilical and Intravenous Oxytocin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is always a debate for choosing the best method for management of the third stage of labour (TSL) in the general practice for reducing the duration of TSL. Although intravenous oxytocin is more extensively used in general practice for managing TSL than intraumbilical, it still needs to be properly investigated among local populations and in local settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor

NCT03395730

Postpartum Haemorrhage With Retained Placenta

UNKNOWN PHASE2

IV vs IM Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage

NCT01608958

Postpartum Hemorrhage

COMPLETED NA

Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor

NCT02680938

Postpartum Hemorrhage

UNKNOWN PHASE1

Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor

NCT01094028

Labor

COMPLETED PHASE3

When and How to Administer Oxytocin for Active Management of Third Stage of Labour

NCT01954186

Postpartum Bleeding

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The findings of this study could identify the better route of oxytocin injection that could guide clinicians and health providers to opt for the better route in their routine practice for the management of TSL in order to reduce the morbidity and mortality of the patients, especially for developing countries like Pakistan, where most of the deliveries are conducted at peripheral or rural centers by a nurse, midwife, or a trained dai.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Labor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intraumbilical oxytocin group

Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

Group Type EXPERIMENTAL

Intraumbilical oxytocin

Intervention Type DRUG

Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

Intravenous oxytocin group

Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

Group Type EXPERIMENTAL

Intravenous oxytocin

Intervention Type DRUG

Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intraumbilical oxytocin

Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

Intervention Type DRUG

Intravenous oxytocin

Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females aged 18-40 years
* With spontaneous vaginal delivery
* Singleton pregnancy
* Gestational age \>37 weeks
* Parity l-5
* Any gravidity

Exclusion Criteria

* Females with intrauterine fetal death
* Malpresentation
* Multiple pregnancy
* Polyhydramnios
* Premature rupture of membranes
* Medical disorders and hypertensive disorders of pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No